PRLR and prostate carcinoma: The eCBs, AEA and 2-AG, and the sCB, HU-210, inhibit the proliferation of human breast and prostate cancer cells via crosstalk between the CB1R, the high-affinity nerve growth factor receptor (NTRK1) and the prolactin receptor (PRLR) signalling pathways [53] (Figure 2).